These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 35397501)

  • 1. Real-world characteristics, treatment experiences and corticosteroid utilisation of patients treated with tofacitinib for moderate to severe ulcerative colitis.
    Chiorean MV; Allegretti JR; Sharma PP; Chastek B; Salese L; Bell EJ; Peterson-Brandt J; Cappelleri JC; Guo X; Khan N
    BMC Gastroenterol; 2022 Apr; 22(1):177. PubMed ID: 35397501
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of Tofacitinib in Ulcerative Colitis Based on Prior Tumor Necrosis Factor Inhibitor Failure Status.
    Sandborn WJ; Peyrin-Biroulet L; Sharara AI; Su C; Modesto I; Mundayat R; Gunay LM; Salese L; Sands BE
    Clin Gastroenterol Hepatol; 2022 Mar; 20(3):591-601.e8. PubMed ID: 33684552
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tofacitinib for ulcerative colitis: results of the prospective Dutch Initiative on Crohn and Colitis (ICC) registry.
    Biemans VBC; Sleutjes JAM; de Vries AC; Bodelier AGL; Dijkstra G; Oldenburg B; Löwenberg M; van Bodegraven AA; van der Meulen-de Jong AE; de Boer NKH; Srivastava N; West RL; Römkens TEH; Horjus Talabur Horje CS; Jansen JM; van der Woude CJ; Hoekstra J; Weersma RK; van Schaik FDM; Hoentjen F; Pierik MJ;
    Aliment Pharmacol Ther; 2020 May; 51(9):880-888. PubMed ID: 32237087
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tofacitinib Salvage Therapy for Children Hospitalized for Corticosteroid- and Biologic-Refractory Ulcerative Colitis.
    Constant BD; Baldassano R; Kirsch J; Mitchel EB; Stein R; Albenberg L
    J Pediatr Gastroenterol Nutr; 2022 Dec; 75(6):724-730. PubMed ID: 36122389
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Superior Effectiveness of Tofacitinib Compared to Vedolizumab in Anti-TNF-experienced Ulcerative Colitis Patients: A Nationwide Dutch Registry Study.
    Straatmijer T; Biemans VBC; Visschedijk M; Hoentjen F; de Vries A; van Bodegraven AA; Bodelier A; de Boer NKH; Dijkstra G; Festen N; Horjus C; Jansen JM; Jharap B; Mares W; van Schaik FDM; Ponsioen C; Romkens T; Srivastava N; van der Voorn MMPJA; West R; van der Woude J; Wolvers MDJ; Pierik M; van der Meulen-de Jong AE; Duijvestein M;
    Clin Gastroenterol Hepatol; 2023 Jan; 21(1):182-191.e2. PubMed ID: 35644343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world evidence of tofacitinib effectiveness and safety in patients with refractory ulcerative colitis.
    Lair-Mehiri L; Stefanescu C; Vaysse T; Laharie D; Roblin X; Rosa I; Treton X; Abitbol V; Amiot A; Bouguen G; Dib N; Fumery M; Pariente B; Carbonnel F; Peyrin-Biroulet L; Simon M; Viennot S; Bouhnik Y
    Dig Liver Dis; 2020 Mar; 52(3):268-273. PubMed ID: 31732444
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-Effectiveness of 5-Aminosalicylate Therapy in Combination With Biologics or Tofacitinib in the Treatment of Ulcerative Colitis.
    Shaffer SR; Huang E; Patel S; Rubin DT
    Am J Gastroenterol; 2021 Jan; 116(1):125-133. PubMed ID: 32947317
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of tofacitinib compared with infliximab, adalimumab, golimumab, vedolizumab and ustekinumab for the treatment of moderate to severe ulcerative colitis in Germany.
    Sardesai A; Dignass A; Quon P; Milev S; Cappelleri JC; Kisser A; Modesto I; Sharma PP
    J Med Econ; 2021; 24(1):279-290. PubMed ID: 33502905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Retrospective Database Analysis: Dose Escalation and Adherence in Patients Initiating Biologics for Ulcerative Colitis.
    Long MD; Cohen RD; Smith TW; DiBonaventura M; Gruben D; Bargo D; Salese L; Quirk D
    Dig Dis; 2022; 40(5):553-564. PubMed ID: 34879378
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Market Access Analysis of Biologics and Small-Molecule Inhibitors for Inflammatory Bowel Disease Among US Health Insurance Policies.
    Dulai PS; Osterman MT; Lasch K; Cao C; Riaz F; Sandborn WJ
    Dig Dis Sci; 2019 Sep; 64(9):2478-2488. PubMed ID: 30923985
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tofacitinib Treatment Safety in Moderate to Severe Ulcerative Colitis: Comparison of Observational Population Cohort Data From the IBM MarketScan® Administrative Claims Database With Tofacitinib Trial Data.
    Curtis JR; Regueiro M; Yun H; Su C; DiBonaventura M; Lawendy N; Nduaka CI; Koram N; Cappelleri JC; Chan G; Modesto I; Lichtenstein GR
    Inflamm Bowel Dis; 2021 Aug; 27(9):1394-1408. PubMed ID: 33324993
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world comparison of effectiveness between tofacitinib and vedolizumab in patients with ulcerative colitis exposed to at least one anti-TNF agent.
    Buisson A; Nachury M; Guilmoteau T; Altwegg R; Treton X; Fumery M; Serrero M; Leclerc E; Caillo L; Pereira B; Amiot A; Bouguen G
    Aliment Pharmacol Ther; 2023 Mar; 57(6):676-688. PubMed ID: 36401585
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systematic review with network meta-analysis: comparative assessment of tofacitinib and biological therapies for moderate-to-severe ulcerative colitis.
    Bonovas S; Lytras T; Nikolopoulos G; Peyrin-Biroulet L; Danese S
    Aliment Pharmacol Ther; 2018 Feb; 47(4):454-465. PubMed ID: 29205421
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving Tofacitinib.
    Winthrop KL; Melmed GY; Vermeire S; Long MD; Chan G; Pedersen RD; Lawendy N; Thorpe AJ; Nduaka CI; Su C
    Inflamm Bowel Dis; 2018 Sep; 24(10):2258-2265. PubMed ID: 29850873
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Short-term effectiveness and safety of tofacitinib in ulcerative colitis - real world data from tertiary medical centers in Israel.
    Avni-Biron I; Bar-Gil Shitrit A; Koslowsky B; Levartovsky A; Kopylov U; Weisshof R; Aviv Cohen N; Maharshak N; Hovel D; Israeli E; Naftali T; Goren I; Snir Y; Ollech JE; Banai-Eran H; Broitman Y; Sharar-Fischler T; Dotan I; Yanai H
    Dig Liver Dis; 2022 Feb; 54(2):192-197. PubMed ID: 34887214
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term Risk of Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving Tofacitinib.
    Winthrop KL; Vermeire S; Long MD; Panés J; Ng SC; Kulisek N; Mundayat R; Lawendy N; Vranic I; Modesto I; Su C; Melmed GY
    Inflamm Bowel Dis; 2023 Jan; 29(1):85-96. PubMed ID: 35648151
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Corticosteroid-Sparing Effects of Filgotinib in Moderately to Severely Active Ulcerative Colitis: Data from the Phase 2b/3 SELECTION Study.
    Loftus EV; Vermeire S; Feagan BG; Le Brun FO; Oortwijn A; Moerch U; Sandborn WJ; Hibi T
    J Crohns Colitis; 2023 Mar; 17(2):211-220. PubMed ID: 36006011
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tofacitinib for the treatment of moderately to severely active ulcerative colitis: a systematic review, network meta-analysis and economic evaluation.
    Lohan C; Diamantopoulos A; LeReun C; Wright E; Bohm N; Sawyer LM
    BMJ Open Gastroenterol; 2019; 6(1):e000302. PubMed ID: 31413856
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systematic review with network meta-analysis: first- and second-line pharmacotherapy for moderate-severe ulcerative colitis.
    Singh S; Fumery M; Sandborn WJ; Murad MH
    Aliment Pharmacol Ther; 2018 Jan; 47(2):162-175. PubMed ID: 29205406
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tofacitinib for Rescue Therapy in Acute Severe Ulcerative Colitis: A Real-world Experience.
    Kotwani P; Terdiman J; Lewin S
    J Crohns Colitis; 2020 Jul; 14(7):1026-1028. PubMed ID: 32020189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.